Reports and Briefs on Pharmaceuticals and Healthcare in Japan

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
Report
Report

2015 Big Pharma Outlook

This report explores and visualizes market dynamics in the Big Pharma peer set out to 2024, using in-house sales forecasts.

Published By Datamonitor
14 Jul 2015 $7500
Buy
Report
Report

Immuno-Oncology Overview

This is an overview of the field of immuno-oncology and the various immuno-oncology classes. Immuno-oncology is one of the most promising and fastest growing areas of cancer research.

Published By Datamonitor
15 Jun 2015 $7500
Buy
Report
Report

Forecast: Rheumatoid Arthritis in the US, Japan, and 5EU

Datamonitor Healthcare uses a patient-based approach to size the rheumatoid arthritis (RA) market in the US, Japan, and five major EU markets from 2014 to 2023, focusing on traditional and biologic disease-modifying therapies.

Published By Datamonitor
24 Apr 2015 $2800
Buy
Report
Report

Treatment: Rheumatoid Arthritis

Through our in-house primary research, Datamonitor Healthcare has produced thorough analysis on rheumatoid arthritis (RA) treatment trends, outcomes, and unmet needs.

Published By Datamonitor
23 Apr 2015 $2800
Buy
Report
Report

Marketed Drugs: Rheumatoid Arthritis

Our marketed drugs analysis gives an overview of market behaviors as well as individual commercial and clinical attractiveness.

Published By Datamonitor
23 Apr 2015 $2800
Buy
Report
Report

Pipeline: Rheumatoid Arthritis

Our pipeline product analysis gives an overview of how pipeline products in general are expected to perform, as well as early-phase projections and individual pipeline forecasts.

Published By Datamonitor
21 Apr 2015 $2800
Buy
Report
Report

The Hepatitis C Market Outlook to 2022

The hepatitis C market will experience a boom as revolutionary interferon-free regimens arrive.

Published By Datamonitor
17 Apr 2013 $2800
Buy
Report
Report

The Inflammatory Bowel Disease Market Outlook to 2021

The IBD market is set to experience considerable change over the next ten years. A number of significant new product launches will reshape the market, with sales for ulcerative colitis forecast to overtake those for Crohn's disease.

Published By Datamonitor
22 Mar 2013 $2800
Buy
Report
Report

The Dyslipidemia Market Outlook to 2021

In the wake of Lipitor’s patent expiry, the dyslipidemia market continues to face increasing genericization leading to falling sales in key drug classes.

Published By Datamonitor
04 Feb 2013 $2800
Buy
Report
Report

The Osteoporosis Market Outlook to 2021

New anti-bone loss drugs soon to reach the osteoporosis market - but generic entry will continue to erode its value.

Published By Datamonitor
17 Jan 2013 $2800
Buy

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.